chronic
obstruct
pulmonari
diseas
copd
extens
influenc
viral
infect
mechan
viral
agent
affect
pathogenesi
prognosi
copd
numer
gener
patient
infecti
exacerb
character
longer
hospit
period
greater
impair
sever
lung
function
paramet
noninfecti
exacerb
prodrom
clinic
outcom
paramet
fail
distinguish
viral
nonvir
induc
ill
case
exacerb
import
infect
respiratori
nonrespiratori
viral
agent
pathogenesi
cours
copd
detail
human
adenoviru
nonrespiratori
virus
includ
human
immunodefici
viru
human
metapneumoviru
influenza
viru
human
rhinoviru
respiratori
syncyti
viru
especi
stress
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
worldwid
major
caus
morbid
mortal
health
care
cost
well
decreas
qualiti
life
individu
patient
thought
caus
complex
interact
host
individu
microbiom
bacteria
virus
environment
influenc
factor
increas
inflammatori
burden
lower
airway
overwhelm
protect
antiinflammatori
defens
mechan
thu
lead
tissu
damag
frequent
exacerb
associ
increas
morbid
mortal
faster
declin
lung
function
poorer
gener
state
health
respiratori
viral
infect
target
epitheli
cell
lung
lead
desquam
microvascular
dilat
edema
inflammatori
cell
infiltr
chang
predispos
lower
airway
bacteri
infect
interfer
mucociliari
clearanc
reduc
bacteri
clearanc
due
macrophag
tabl
predomin
viral
bacteri
infect
neither
associ
sever
exacerb
stage
copd
nevertheless
viral
exacerb
associ
higher
durat
hospit
stay
averag
day
bacteri
exacerb
averag
day
viral
infect
import
caus
common
copd
exacerb
half
twothird
exacerb
virus
caus
pathogen
combin
bacteri
viral
infect
identifi
exacerb
dual
infect
often
sever
although
increas
sever
confirm
studi
neither
clinic
biolog
marker
eg
procalcitonin
creactiv
protein
crp
reliabl
distinguish
viru
induc
exacerb
exacerb
due
caus
though
significantli
increas
neg
correl
forc
expiratori
volum
within
virusinduc
exacerb
indic
relat
virusinduc
inflamm
airway
obstruct
singl
viru
speci
frequent
detect
stabl
copd
patient
detect
one
viru
speci
usual
associ
exacerb
gener
virus
commonli
detect
patient
sever
airway
diseas
optim
vaccin
antivir
treatment
might
increas
prognosi
individu
chronic
respiratori
diseas
host
respons
viral
infect
dysregul
copd
respiratori
virus
noninfecti
patholog
process
lung
human
copd
shown
activ
innat
immun
axi
lead
increas
number
invari
natur
killer
tcell
inktcel
altern
activ
macrophag
lung
exposur
cigarett
smoke
induc
alter
innat
immun
respons
viral
infect
chang
hasten
alveolar
destruct
typic
emphysema
least
mous
model
concert
find
virus
caus
sever
diseas
exacerb
heighten
inflammatori
respons
acceler
loss
lung
function
well
increas
symptomatolog
mortal
smoke
copd
patient
compar
caus
exacerb
copd
addit
cigarett
smoke
enhanc
parenchym
airway
inflamm
well
apoptosi
emphysema
airway
fibrosi
process
induc
viral
pathogenassoci
molecular
pattern
pamp
poli
c
result
earli
induct
type
interferon
ifn
later
induct
activ
doublestrand
rnadepend
protein
kinas
pkr
well
eukaryot
initi
tolllik
receptor
depend
independ
pathway
well
pathway
depend
mitochondri
antivir
signal
protein
mav
receptor
pkr
involv
follow
review
demonstr
import
respiratori
nonrespiratori
viral
agent
pathogenesi
cours
copd
special
emphasi
human
adenoviru
hadv
human
coronaviru
hcov
nonrespiratori
virus
human
metapneumoviru
hmpv
influenza
viru
ifv
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
tabl
latent
hadv
infect
play
import
role
pathogenesi
copd
doublestrand
dna
virus
like
hadv
abl
persist
epitheli
airway
cell
long
acut
infect
clear
region
adenovir
genom
adenovir
protein
remain
stabl
cell
latent
infect
viral
gene
express
protein
level
without
replic
complet
virion
protein
detect
often
patient
copd
healthi
subject
region
adenovirus
found
epitheli
cell
copd
chronic
bronchiti
patient
patient
asthma
normal
volunt
china
furthermor
dna
detect
copd
patient
patient
chronic
bronchiti
newer
data
suggest
adenoviru
dna
mere
infrequ
detect
respiratori
secret
patient
copd
adenoviru
detect
similar
frequenc
exacerb
clinic
stabl
copd
patient
express
adenovir
transactiv
protein
associ
amplif
cigarett
smokeinduc
inflammatori
respons
infect
lead
independ
increas
number
cell
wherea
cigarett
smoke
lead
higher
number
cell
inflammatori
infiltr
latent
infect
adenovir
agent
also
caus
steroid
resist
eosinophil
compon
allerg
inflammatori
respons
adenovir
transfect
transform
primari
human
bronchial
epitheli
hbe
cell
upregul
product
mediat
clinic
relev
pathogenesi
copd
protein
alter
express
growth
factor
connect
tissu
growth
factor
ctgf
well
transform
growth
factor
mrna
protein
express
upregul
hbe
cell
vitro
experi
demonstr
upregul
ctgf
independ
secret
growth
medium
hbe
cell
contain
cytokeratin
cell
express
mesenchym
marker
vimentin
muscl
actin
latent
infect
epitheli
cell
adenoviru
contribut
airway
remodel
copd
viral
protein
induc
ctgf
express
shift
cell
mesenchym
phenotyp
lipopolysaccharid
lp
stimul
hbe
cell
vitro
increas
intercellular
adhes
well
mrna
protein
express
compar
control
cell
also
induc
higher
promot
activ
higher
nuclear
bind
activ
nuclear
extract
transfect
control
howev
even
gene
express
enhanc
solubl
express
recruit
inflammatori
cell
airway
copd
lung
lead
excess
product
lung
epitheli
cell
tabl
persist
adenovir
infect
describ
possibl
caus
nonremit
airway
obstruct
children
howev
chronic
obstruct
bronchiti
inadequ
respons
inhal
steroid
bronchodil
therapi
rather
rare
disord
age
group
nevertheless
adenovir
infect
might
act
starter
chronic
obstruct
bronchiti
children
childhood
infect
respiratori
tract
adenovir
agent
repres
independ
risk
factor
pathogenesi
copd
cigarett
smoker
major
role
hbov
infect
adult
acut
exacerb
copd
unlik
hbov
mere
infrequ
isol
upper
lower
respiratori
tract
specimen
copd
patient
irrespect
presenc
absenc
exacerb
hcov
particular
shown
trigger
acut
respiratori
ill
elderli
adult
copd
although
hcov
infect
copd
patient
usual
less
sever
influenza
infect
associ
multipl
respiratori
system
symptom
well
hospit
tabl
even
nonrespiratori
virus
like
epsteinbarr
viru
ebv
hepat
c
viru
hcv
human
immunodefici
viru
hiv
affect
neg
cours
copd
latent
infect
seem
play
undeni
role
pathogenesi
diseas
ebv
associ
pulmonari
fibrosi
copd
ebv
dna
frequent
identifi
respiratori
tract
copd
patient
comparison
nonaffect
smoker
smoker
without
symptom
copd
rare
ebv
sputum
viru
present
exacerb
also
time
stabl
diseas
suggest
infect
persist
ebv
detect
nearli
patient
copd
demonstr
respiratori
tract
less
nonobstruct
smoker
smoker
infect
ebv
increas
risk
develop
copd
one
case
herp
simplex
viru
type
tracheobronch
nonimmunosuppress
individu
repeat
exacerb
copd
respond
convent
treatment
describ
expect
diseas
respond
well
acyclovirbas
therapi
liver
diseas
associ
high
preval
copd
gener
hepat
viru
infect
particular
show
nonsignific
tendenc
toward
associ
copd
prolong
applic
high
dose
system
corticosteroid
addit
inhal
corticosteroid
demonstr
increas
risk
hepat
b
viru
hbv
reactiv
chronic
hcv
infect
seem
acceler
worsen
lung
function
copd
patient
hcvposit
patient
show
lower
higher
bodeindex
hcvneg
individu
even
consequ
therapi
stop
declin
preval
chronic
hcv
infect
increas
copd
patient
comparison
healthi
blood
donor
hiv
risk
factor
develop
progress
copd
infect
hiv
associ
copd
acceler
emphysema
develop
chronic
bronchiti
small
airway
abnorm
nonspecif
airway
hyperrespons
respiratori
symptom
includ
dyspnea
cough
phlegm
product
extrem
common
hivseroposit
hiv
individu
patient
increas
risk
develop
respiratori
symptom
even
prior
onset
acquir
immunodefici
syndrom
aid
relat
pulmonari
complic
commonli
show
reduc
pulmonari
diffus
capac
dlco
hiv
patient
diffus
impair
demonstr
promin
reduct
capillari
blood
volum
v
c
despit
wellpreserv
total
lung
capac
tlc
evid
interstiti
fibrosi
evid
earli
emphysema
significantli
correl
dlco
current
prior
cigarett
smoke
import
predictor
respiratori
symptom
suscept
effect
cigarett
smoke
heighten
hiv
patient
copd
moder
dyspnea
shown
significantli
increas
hiv
copd
patient
hivtrigg
acceler
onset
smokinginduc
emphysema
could
effect
cytotox
lymphocyt
whose
count
increas
hiv
individu
emphysema
tabl
concordantli
use
antiretrovir
agent
lamivudin
associ
signific
reduct
dyspnea
hmpv
infect
virtual
children
age
year
pathogen
may
contribut
exacerb
copd
shown
lead
seriou
sequela
copd
patient
consid
possibl
viral
trigger
acut
exacerb
asymptomat
carriag
unlik
howev
viru
detect
small
number
patient
acut
exacerb
copd
nevertheless
rare
case
prolong
morbid
hospit
stay
well
increas
mortal
describ
particularli
elderli
pneumonia
hypoxem
global
respiratori
failur
requir
mechan
ventil
lymphopenia
describ
addit
hmpv
infect
predispos
bacteri
pneumonia
coinfect
respiratori
syncyti
viru
rsv
lead
increas
sever
clinic
diseas
ifv
infect
caus
excess
morbid
mortal
copd
patient
vice
versa
copd
risk
factor
particularli
sever
cours
influenza
infect
influenza
infect
lead
exacerb
result
reduc
qualiti
life
hospit
even
death
sever
case
viru
primarili
infect
respiratori
tract
lead
fulmin
primari
viral
secondari
bacteri
pneumonia
cigarett
smoke
may
play
import
etiolog
role
topic
immunosuppress
cigarett
smoke
extract
cse
inhibit
influenzainduc
protein
mrna
express
major
antivir
cytokin
mrna
express
viralmedi
retino
acid
induc
gene
rigi
mrna
protein
express
latter
believ
import
recognit
respons
rna
virus
like
influenza
viru
suppress
prevent
nacetylcystein
glutathion
smokeexpos
mice
ifv
infect
associ
increas
express
ccchemokin
receptor
chemokin
monocyt
chemotact
protein
mcp
well
cxcchemokin
receptor
chemokin
keratinocyt
chemoattract
kc
macrophag
inflammatori
granulocyt
chemotact
comparison
control
mice
upon
infect
two
antigen
present
viral
surfac
ifv
hemagglutinin
neuraminidas
play
crucial
role
induct
human
ifv
immun
sinc
mani
vari
allel
antigen
appear
due
antigen
drift
immun
popul
blunt
annual
antiinfluenza
vaccin
therefor
recommend
patient
copd
reduc
rate
sever
copd
exacerb
slow
diseas
progress
way
inform
campaign
gain
attent
risk
group
like
copd
patient
advis
particularli
epidem
vaccin
usual
consist
cocktail
three
strain
must
annual
updat
due
continu
antigen
chang
ifv
inactiv
influenza
vaccin
use
year
excel
safeti
record
influenza
vaccin
associ
minim
local
advers
reaction
usual
caus
system
advers
reaction
neither
clinic
exacerb
advers
affect
lung
function
regardless
sever
airflow
obstruct
trival
inactiv
influenza
viru
vaccin
tvv
trival
live
coldadapt
influenza
viru
vaccin
caivt
like
stimul
protect
immun
respons
tvv
combin
caivt
immunogen
tvv
alon
receipt
coldadapt
influenza
viru
vaccin
associ
temporari
stabil
copd
acut
respiratori
ill
associ
worsen
concern
function
statu
subject
wellb
season
influenza
vaccin
patient
sever
copd
trival
influenza
split
virion
vaccin
lead
increas
antiinfluenza
b
igg
level
reduc
hospit
pneumonia
need
intens
care
treatment
intraderm
vaccin
reduc
dose
may
consid
countri
restrict
access
influenza
vaccin
due
consider
cost
interest
side
effect
season
influenza
vaccin
induct
crossneutr
antibodi
ifv
demonstr
elderli
copd
patient
thailand
although
influenza
vaccin
highli
effect
prevent
influenzarel
acut
respiratori
ill
regardless
sever
copd
prevent
acut
respiratori
ill
unrel
influenza
effect
influenza
vaccin
prevent
overal
acut
respiratori
ill
patient
copd
depend
much
proport
influenzarel
acut
respiratori
ill
contribut
incid
total
acut
respiratori
ill
start
earli
antivir
drug
especi
neuraminidas
inhibitor
prescrib
adjunct
nonspecif
intervent
attempt
shorten
diseas
durat
prevent
complic
case
influenza
infect
howev
effect
antivir
drug
specif
patient
copd
proven
far
dexamethason
lead
reduct
chemokin
level
neutrophilia
smokeexpos
ifvinfect
mice
associ
worsen
symptom
howev
treatment
peroxisom
proliferatoractiv
pparg
agonist
like
pioglitazon
show
promis
effect
mice
hrv
member
famili
picornavirida
caus
pathogen
half
acut
viral
infect
upper
respiratori
tract
virus
associ
acut
exacerb
respiratori
diseas
includ
asthma
sinus
otiti
media
copd
fact
repres
common
infecti
caus
chronic
obstruct
pulmonari
diseas
exacerb
viral
symptom
high
predict
valu
copd
patient
picornaviru
infect
includ
rhinorrhea
sorethroat
discret
increas
cough
usual
associ
increas
product
neuropeptid
leukotrien
alter
express
neural
receptor
increas
airway
mucu
product
hrv
wellrecogn
caus
common
cold
also
abl
induc
ill
lower
respiratori
tract
viru
identifi
nearli
exacerb
copd
typic
associ
elev
lower
airway
level
may
mediat
lower
airway
symptom
chronic
obstruct
pulmonari
diseas
exacerb
contrast
interferon
product
bronchoalveolar
cell
copdpati
impair
associ
higher
viru
load
patient
without
copd
symptom
seriou
case
bacteri
coinfect
exacerb
hrv
haemophilu
influenza
associ
higher
bacteri
load
serum
level
exacerb
one
pathogen
exacerb
cold
symptom
marker
put
viral
infect
bacteri
pathogen
declin
greater
symptom
count
higher
caus
bacteri
pathogen
alon
frequent
exacerb
experi
significantli
cold
infrequ
exacerb
howev
likelihood
exacerb
cold
unaffect
exacerb
frequenc
exacerb
frequenc
chronic
obstruct
pulmonari
diseas
associ
increas
frequenc
acquir
common
cold
rather
increas
propens
exacerb
cold
acquir
patient
experienc
frequent
cold
significantli
higher
exposur
cigarett
smoke
hrv
capabl
effici
replic
experiment
infect
vitro
temperatur
present
tracheobronchi
tree
caus
product
infect
increas
cytokin
chemokin
level
upregul
cell
surfac
marker
human
bronchial
epitheli
cell
replic
increas
express
tolllik
receptor
mrna
protein
cell
surfac
human
bronchial
epitheli
cell
import
mediat
antivir
respons
also
known
protein
play
role
pathogenesi
hrvinduc
cold
hrvinduc
exacerb
copd
induc
infect
primari
cultur
human
airway
epitheli
cell
human
bronchial
epitheli
cell
rhinovirus
ligand
receptor
found
activ
type
tlymphocyt
natur
killer
cell
gener
requir
intracellular
viru
capabl
replic
depend
prior
induct
type
interferon
transfect
synthet
doublestrand
rna
epitheli
cell
induc
robust
product
wherea
transfect
singlestrand
rna
effect
induct
gene
express
depend
upon
activ
well
transcript
factor
recognit
sequenc
upstream
promot
vivo
infect
human
volunt
strikingli
increas
protein
nasal
lavag
symptomat
cold
level
correl
symptom
sever
viral
titer
number
lymphocyt
airway
secret
thu
suit
potenti
biomark
rhinovirusinduc
exacerb
copd
tabl
cellular
level
elev
protein
level
growthrel
measur
rhinoviru
stimul
rhinovirusencod
proteinas
trigger
vitro
activ
monocytederiv
dendrit
cell
induct
immun
respons
tcell
laboratori
mice
intranas
instal
rhinoviru
proteinas
lead
increas
airway
hyperreact
lung
inflamm
product
tcell
alter
immun
respons
believ
associ
worsen
dyspnea
respiratori
failur
copd
patient
cigarett
smoke
extract
differenti
modul
rhinovirusinduc
chemokin
profil
human
airway
epitheli
cell
increas
rhinovirusinduc
stimul
product
via
mrna
stabil
inhibit
rhinovirusinduc
product
via
transcript
regul
safe
effect
antivir
agent
desir
prevent
treatment
hrv
infect
copd
patient
advanc
antivir
agent
hrv
fection
pleconaril
viral
capsidbind
inhibitor
potent
highli
specif
vitro
activ
major
serotyp
rhinoand
enterovirus
rsv
infect
common
caus
childhood
bronchiol
also
import
ill
elderli
highrisk
adult
diseas
burden
similar
nonpandem
influenza
popul
preval
vaccin
influenza
high
rsv
rna
identifi
revers
transcriptasepolymeras
chain
reaction
rtpcr
high
percentag
copd
patient
rsv
infect
patient
copd
associ
symptomat
respiratori
ill
measur
immun
respons
symptom
usual
milder
adult
children
sever
cours
describ
viral
shed
usual
low
adult
make
diagnost
challeng
stress
need
sensit
molecular
tool
therapeut
effect
ribavirin
palivizumab
affect
adult
yet
poorli
investig
sever
immunocompromis
patient
patient
sever
respiratori
failur
regularli
treat
effect
rsv
vaccin
may
offer
benefit
adult
immun
would
presum
effect
howev
effect
vaccin
avail
yet
increas
suscept
copd
patient
rsv
believ
due
rsvor
immun
responseinduc
pulmonari
effect
alter
age
environment
exposur
genet
copd
combin
rsv
lead
activ
recruit
tcell
amplifi
skew
immun
respons
toward
intens
patholog
includ
mucu
product
remodel
airway
copd
patient
despit
contradicti
report
sever
studi
suggest
asymptomat
persist
rsv
copd
detect
frequent
stabl
copd
patient
patient
diseas
exacerb
contribut
factor
potenti
rsv
persist
copd
patient
compris
impair
antivir
immun
due
cigarett
smoke
copd
induct
skew
type
thelper
cell
respons
rsv
consecut
immun
evas
antagon
antivir
cytokin
mimick
chemokin
inhibit
apoptosi
enter
immuneprivileg
cell
pulmonari
neuron
antigen
drift
viru
respiratori
virus
repres
import
trigger
acut
exacerb
copd
pathogenesi
infiltr
copd
airway
tcell
give
hint
suggest
viral
agent
could
influenc
cours
copd
tabl
viral
infect
induc
proinflammatori
chemokin
product
childhood
respiratori
infect
independ
risk
factor
subsequ
develop
copd
patient
moder
sever
copd
presenc
viru
upper
airway
secret
strongli
associ
develop
copd
exacerb
viral
respiratori
tract
infect
causal
associ
hospit
commun
associ
exacerb
hrv
hcov
ifv
rsv
parainfluenza
viru
hpiv
hadv
hmpv
import
viral
caus
chronic
obstruct
pulmonari
diseas
exacerb
tabl
exacerb
sever
prolong
recoveri
time
howev
viral
infect
appear
effect
subsequ
readmiss
mortal
rate
viral
detect
rate
independ
valu
copd
patient
colon
lower
respiratori
tract
bacteri
viral
infecti
agent
result
chronif
inflammatori
process
progress
copd
colon
correl
sever
diseas
virus
rsv
stimul
helper
tlymphocyt
type
pattern
immun
respons
associ
allerg
inflamm
virus
hadv
appear
persist
latent
infect
airway
patient
copd
adenovir
protein
capabl
amplifi
host
gene
possibl
includ
involv
cigarett
smokeinduc
lung
inflamm
bacteri
exacerb
copd
also
frequent
associ
viral
infect
exacerb
case
due
nontyp
h
influenza
associ
evid
acut
coexist
viral
infect
patient
copd
exacerb
requir
mechan
ventil
infect
viral
pathogen
statist
signific
differ
prodrom
clinic
characterist
outcom
group
without
viral
infect
howev
patient
infecti
exacerb
suffer
prolong
hospit
greater
impair
sever
lung
function
paramet
noninfecti
exacerb
airway
neutrophilia
relat
exacerb
sever
regardless
viral
andor
bacteri
infect
eosinophilia
good
predictor
viral
exacerb
valu
sputum
inflammatori
marker
increas
copd
patient
symptom
common
cold
detect
hrv
exacerb
thu
suggest
viral
infect
lead
greater
airway
inflamm
thu
sever
exacerb
express
airway
neutrophil
inflamm
marker
increas
time
acut
copd
exacerb
declin
month
later
acut
inflammatori
respons
appear
occur
independ
demonstr
viral
bacteri
airway
infect
patient
document
infect
demonstr
greater
increas
sputum
level
inflammatori
cytokin
exacerb
compar
patient
without
demonstr
infect
effect
demonstr
myeloperoxidas
mpo
tumor
necrosi
increas
plasma
fibrinogen
level
sign
system
inflammatori
effect
copd
exacerb
picornaviru
coronaviru
influenza
viru
common
infecti
agent
associ
copd
infect
rsv
influenza
b
hpiv
hcov
picornaviru
also
detect
nest
rtpcr
upper
lower
respiratori
tract
specimen
virus
significantli
often
detect
hospit
copd
patient
nonhospit
one
induc
sputum
contain
respiratori
virus
frequent
higher
concentr
nasal
lavag
copd
patient
pcr
sensit
method
detect
viral
pathogen
tabl
one
signific
disadvantag
technolog
lack
abil
differenti
infect
colon
accord
recent
review
weight
mean
preval
respiratori
viral
infect
copd
exacerb
viral
exacerb
frequent
report
europ
follow
usa
australia
asia
picornavirus
lead
western
countri
influenza
viru
asia
weight
mean
preval
respect
virus
picornaviru
ifv
rsv
hcov
hpiv
hadv
hmpv
tabl
lower
quantit
relev
ifv
studi
western
countri
might
attribut
consider
high
vaccin
rate
accord
dimopoulo
et
al
common
viru
detect
copd
exacerb
compris
rsv
subtyp
b
ifv
subtyp
b
c
hrv
hpiv
subtyp
b
bacteri
caus
identifi
patient
combin
bacterialvir
infect
tabl
contrast
studi
seemung
cowork
demonstr
common
respiratori
virus
detect
copd
exacerb
hrv
nonrespiratori
syncyti
viru
rsv
tabl
latter
one
often
detect
stabl
copd
patient
describ
viral
exacerb
due
hrv
associ
frequent
exacerb
cold
increas
dyspnea
higher
total
symptom
count
present
longer
median
symptom
recoveri
period
day
tendenc
toward
higher
plasma
fibrinogen
increas
serum
level
rsv
detect
associ
higher
inflammatori
marker
level
presenc
nonrespiratori
syncyti
viru
epitheli
cell
princip
site
viral
infect
airway
play
central
role
viral
modul
airway
inflamm
releas
varieti
cytokin
chemokin
growth
factor
epithelium
also
contribut
host
innat
defens
respons
viral
infect
releas
product
antivir
andor
lead
increas
recruit
dendrit
cell
lymphocyt
evid
support
role
epitheli
cell
specif
immun
although
respons
convent
cell
immun
system
viral
infect
domin
factor
regard
antivir
defens
depend
least
part
network
mucos
epitheli
cell
macrophag
network
compromis
host
highli
suscept
infect
network
compon
engin
provid
increas
resist
attempt
improv
antivir
defens
may
also
lead
perman
inflammatori
airway
diseas
long
infect
clear
tabl
develop
vitro
experiment
model
viru
infect
identifi
nitric
oxid
possibl
therapeut
target
augment
antivir
immun
target
develop
antiinflammatori
therapi
littl
known
yet
detail
viral
agent
influenc
pathogenesi
copd
still
remain
field
intens
research
mani
cellular
molecular
mechan
virus
caus
exacerb
still
undetermin
use
biomark
repres
potenti
diagnost
tool
could
provid
new
insight
pathogenesi
viral
infect
copd
patient
current
therapi
effect
prevent
treatment
virusinduc
exacerb
copd
exacerb
therefor
major
unmet
medic
need
better
understand
viral
infect
support
progress
copd
could
lead
new
therapeut
approach
improv
outcom
exacerb
prognosi
copd
